Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

More than 90% of women with polycystic ovary syndrome achieved at least 10% total weight loss after 10 months of tirzepatide ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Tirzepatide was linked to improved weight loss outcomes in patients with PCOS, especially those who used a digital weight ...

Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...

Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, ...

New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, ...

ATLANTA — Tirzepatide appeared highly effective in reducing weight among women with polycystic ovary syndrome (PCOS) and overweight or obesity, real-world data from a retrospective analysis of over ...

GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...

P opular weight-loss drugs known as GLP-1s could soon become more affordable for Americans. On Thursday, the Trump ...

A solid clinical win for a promising candidate helped jolt the stock a few months ago. And just last week, the company's ...